CRANBURY, N.J., Oct. 21, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 10th Annual BIO Investor Forum on Wednesday, October 26, 2011 at 2:00 p.m. Pacific Time. Hosted by the Biotechnology Industry Organization (BIO), the 10th Annual BIO Investor Forum will take place October 25-26 at the Palace Hotel in San Francisco, CA.
Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs. Palatin Technologies has an ongoing Phase 2B clinical trial with bremelanotide, a peptide melanocortin receptor agonist, for treatment of female sexual dysfunction in premenopausal women.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.
SOURCE Palatin Technologies, Inc.